newsfilter
← Latest News
GlobeNewswire·

NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results

Advanced programs across NGM Bio's pipeline in retinal diseases, oncology and liver and metabolic diseases during the fourth quarter and beginning of 2022: Obtained Fast Track designation from the U.S. Food and Drug Administration (FDA) for NGM621, an